The balance players of the adaptive immune system

Research output: Contribution to journal › Review › Research › peer-review

Standard

The balance players of the adaptive immune system. / Andersen, Mads Hald.

In: Cancer Research, Vol. 78, No. 6, 2018, p. 1379-1382.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Andersen, MH 2018, 'The balance players of the adaptive immune system', Cancer Research, vol. 78, no. 6, pp. 1379-1382. https://doi.org/10.1158/0008-5472.CAN-17-3607

APA

Andersen, M. H. (2018). The balance players of the adaptive immune system. Cancer Research, 78(6), 1379-1382. https://doi.org/10.1158/0008-5472.CAN-17-3607

Vancouver

Andersen MH. The balance players of the adaptive immune system. Cancer Research. 2018;78(6):1379-1382. https://doi.org/10.1158/0008-5472.CAN-17-3607

Author

Andersen, Mads Hald. / The balance players of the adaptive immune system. In: Cancer Research. 2018 ; Vol. 78, No. 6. pp. 1379-1382.

Bibtex

@article{1e83eee71d2348e0afe2e86f89b8ce54,
title = "The balance players of the adaptive immune system",
abstract = "Equilibrium between immune activation and suppression may be necessary to maintain immune homeostasis, because proinflammatory effector T cells (defined as antiregulatory T cells) counteract the functions of regulatory immune cells. These self-reactive T cells recognize human leukocyte antigen (HLA)–restricted epitopes derived from proteins expressed by regulatory immune cells such as IDO, PD-L1, PD-L2, or arginase. The activation of such proinflammatory effector T cells offers a novel way to directly target the tumor microenvironment, potentially giving them considerable clinical value, especially in patients with cancer. Vaccination against genetically stable cells with regular HLA expression is an attractive way to directly target immunosuppressive cells in addition to attracting proinflammatory cells into the tumor microenvironment. Importantly, vaccination toward IDO or PD-L1 to potentiate such T cells have proven safe, with minimal toxicity in the clinical phase I trials conducted thus far.",
author = "Andersen, {Mads Hald}",
year = "2018",
doi = "10.1158/0008-5472.CAN-17-3607",
language = "English",
volume = "78",
pages = "1379--1382",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research",
number = "6",

}

RIS

TY - JOUR

T1 - The balance players of the adaptive immune system

AU - Andersen, Mads Hald

PY - 2018

Y1 - 2018

N2 - Equilibrium between immune activation and suppression may be necessary to maintain immune homeostasis, because proinflammatory effector T cells (defined as antiregulatory T cells) counteract the functions of regulatory immune cells. These self-reactive T cells recognize human leukocyte antigen (HLA)–restricted epitopes derived from proteins expressed by regulatory immune cells such as IDO, PD-L1, PD-L2, or arginase. The activation of such proinflammatory effector T cells offers a novel way to directly target the tumor microenvironment, potentially giving them considerable clinical value, especially in patients with cancer. Vaccination against genetically stable cells with regular HLA expression is an attractive way to directly target immunosuppressive cells in addition to attracting proinflammatory cells into the tumor microenvironment. Importantly, vaccination toward IDO or PD-L1 to potentiate such T cells have proven safe, with minimal toxicity in the clinical phase I trials conducted thus far.

AB - Equilibrium between immune activation and suppression may be necessary to maintain immune homeostasis, because proinflammatory effector T cells (defined as antiregulatory T cells) counteract the functions of regulatory immune cells. These self-reactive T cells recognize human leukocyte antigen (HLA)–restricted epitopes derived from proteins expressed by regulatory immune cells such as IDO, PD-L1, PD-L2, or arginase. The activation of such proinflammatory effector T cells offers a novel way to directly target the tumor microenvironment, potentially giving them considerable clinical value, especially in patients with cancer. Vaccination against genetically stable cells with regular HLA expression is an attractive way to directly target immunosuppressive cells in addition to attracting proinflammatory cells into the tumor microenvironment. Importantly, vaccination toward IDO or PD-L1 to potentiate such T cells have proven safe, with minimal toxicity in the clinical phase I trials conducted thus far.

U2 - 10.1158/0008-5472.CAN-17-3607

DO - 10.1158/0008-5472.CAN-17-3607

M3 - Review

C2 - 29440147

AN - SCOPUS:85047754078

VL - 78

SP - 1379

EP - 1382

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 6

ER -

ID: 208885354